Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.

Read narrative

Sanofi Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Sanofi
Historische aandelenkoersen
Huidige aandelenkoers	€43.18
52 Week Hoogtepunt	€53.36
52 Week Laag	€43.10
Bèta	0.28
1 maand verandering	-7.79%
3 maanden verandering	-9.72%
1 Jaar Verandering	-17.17%
3 jaar verandering	-20.60%
5 jaar verandering	-17.82%
Verandering sinds IPO	45.05%

Recent nieuws en updates

Recent updates

Seeking Alpha • Apr 20

What To Expect From Sanofi In Q1 2026

Summary On April 23, Sanofi will report its results for the first quarter of 2026. As a reminder, its revenue grew 23.1% year-over-year to $13.53 billion in Q4 last year. Meanwhile, Sanofi’s non-GAAP P/E ratio [FWD] is 9.66x, which, in my view, clearly indicates that it is trading at a discount. Also on April 13, Dupixent, its mega-blockbuster, received approval from the EC for the treatment of certain children with chronic spontaneous urticaria. Further, I'll discuss other factors that, in my view, make Sanofi's risk/reward profile even more attractive now that its stock is in the accumulation phase. Read the full article on Seeking Alpha

Seeking Alpha • Feb 19

Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth

Summary Sanofi's deep partnership with OpenAI could be a huge differentiating factor as OpenAI's agentic models grow in capabilities. OpenAI's "Deep Research" tool is already incredibly promising for Sanofi in its ability to dramatically boost the productivity of researchers. Sanofi's strong financials provide a solid base to fuel AI-driven growth. Sanofi still faces many competitive and regulatory challenges. Read the full article on Seeking Alpha

Seeking Alpha • Jan 29

Time To Be Bullish On Sanofi Ahead Of Its Earnings

Summary Dupixent continues leading among SNY’s portfolio, and it’s poised for up to $20 billion in peak sales. SNY’s recent Opella divestiture marks a pivot away from consumer health items like vitamins and supplements, bringing in roughly $8.7 billion in proceeds. SNY’s RSV vaccine, called Beyfortus, was a key driver for its previous quarter, and its Q4 could be a repeat since it’s typically seasonally strong for vaccines. The company also has a robust late-stage pipeline across multiple other indications, and I think we could see interesting updates for new IPs in 2025. Currently, SNY seems cheap relative to its peers, and the stock has yet to reach its previous 2024 highs. So, I think it’s a good time to buy SNY ahead of earnings. Read the full article on Seeking Alpha

Rendement voor aandeelhouders

	SNY	US Pharmaceuticals	US Markt
7D	-7.3%	-1.9%	2.1%
1Y	-17.2%	33.3%	30.6%

Rendement versus industrie: SNY presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 33.3 % opleverde.

Rendement versus markt: SNY presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.6 % opleverde.

Prijsvolatiliteit

Is SNY's price volatile compared to industry and market?
SNY volatility
SNY Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stabiele aandelenkoers: SNY heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van SNY is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1994	74,846	Belen Garijo Lopez	www.sanofi.com

Sanofi houdt zich bezig met onderzoek, ontwikkeling, productie en marketing van therapeutische oplossingen. Het bedrijf levert vaccins voor immunologie en ontstekingen, neurologie voor zeldzame ziekten, oncologie en andere vaccins. Het biedt ook kindervaccins tegen poliomyelitis, kinkhoest en haemophilus influenzae type b (Hib); bescherming tegen respiratoir syncytieel virus en hexavalente combinatievaccins die hepatitis A-, tyfus-, gele koorts- en rabiësvaccins omvatten.

Sanofi Samenvatting

Hoe verhouden de winst en inkomsten van Sanofi zich tot de beurswaarde?
SNY fundamentele statistieken
Marktkapitalisatie	US$103.90b
Inkomsten(TTM)	US$5.67b
Inkomsten(TTM)	US$55.59b

18.3x

Koers/Winstverhouding

1.9x

P/S-verhouding

Is SNY overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SNY resultatenrekening (TTM)
Inkomsten	€47.35b
Kosten van inkomsten	€13.09b
Brutowinst	€34.26b
Overige uitgaven	€29.44b
Inkomsten	€4.83b

Laatst gerapporteerde inkomsten

Mar 31, 2026

Volgende inkomensdatum

Jul 30, 2026

Winst per aandeel (EPS)	4.02
Brutomarge	72.36%
Nettowinstmarge	10.20%
Schuld/Eigen Vermogen Verhouding	24.9%

Hoe presteerde SNY op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

5.6%

Huidig dividendrendement

102%

Uitbetalingsratio

Betaalt SNY een betrouwbaar dividend?

Zie SNY dividendgeschiedenis en benchmarks

Wanneer moet je SNY kopen om een aanstaand dividend te ontvangen?
Sanofi dividenddata
Ex Dividend Datum	May 04 2026
Betaaldatum dividend	Jun 03 2026
Dagen tot Ex-dividend	6 days
Dagen tot dividendbetaaldatum	24 days

Betaalt SNY een betrouwbaar dividend?

Zie SNY dividendgeschiedenis en benchmarks

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/07 03:36
Aandelenkoers aan het einde van de dag	2026/05/07 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Sanofi wordt gevolgd door 53 analisten. 18 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
null null	Banco de Sabadell. S.A.

Sanofi (SNY) Aandelenoverzicht

Beloningen

Risicoanalyse

Looking to be second time lucky with a game-changing new product

Sanofi Concurrenten

Bristol-Myers Squibb

Pfizer

Zoetis

Teva Pharmaceutical Industries

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi Announces Board and Committee Changes

Sanofi Approves Ordinary Annual Dividend, Payable on May 7, 2026

Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Sanofi Receives US Approval for Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi Announces Board and Committee Changes

Sanofi Approves Ordinary Annual Dividend, Payable on May 7, 2026

Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Sanofi Receives US Approval for Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children

What To Expect From Sanofi In Q1 2026

Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike in Head-To-Head Study

Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria

Sanofi Becomes Market Authorization Holder for Nuvaxovid in Canada

Sanofi Announces Lunsekimig Meets Primary And Key Secondary Endpoints In Phase 2 Respiratory Studies In Asthma And CRSwNP

Sanofi Announces EU Approval of Rezurock for Treatment of Chronic Graft-Versus-Host Disease

Sanofi Presents New Results from Amlitelimab Phase 3 Studies in Atopic Dermatitis

Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid

Sanofi Earns Breakthrough Therapy Designation in the Us for Venglustat for Type 3 Gaucher Disease

Sanofi, Annual General Meeting, Apr 29, 2026

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Sanofi's Rilzabrutinib Designates Breakthrough Therapy in the Us and Orphan Drug in Japan for the Treatment of Cold Autoimmune Hemolytic Anemia

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi (ENXTPA:SAN) completed the acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX).

Sanofi's Venglustat Met All Primary Endpoints in A Phase 3 Study of Type 3 Gaucher Disease

Sanofi’s Rezurock Recommends for EU Approval by the CHMP to Treat Chronic Graft-vs-Host Disease

Sanofi Provides Earnings Guidance for the Year 2026

Sanofi Proposes Dividend for 2025

Sanofi's Amlitelimab Confirms its Potential in Atopic Dermatitis

Sanofi Announces Approval of Myqorzo and Redemplo in China

Sanofi's Tzield Accepts for Priority Review in the Us for Young Children with Stage 2 Type 1 Diabetes

Sanofi (ENXTPA:SAN) agreed to acquire Dynavax Technologies Corporation (NasdaqGS:DVAX) for $1.9 billion.

Sanofi Provides Update on Tolebrutinib in Primary Progressive Multiple Sclerosis

Sanofi's Qfitlia and Cablivi Approves in China, Expanding Care for Rare Diseases

Sanofi (ENXTPA:SAN) completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Sanofi's Teizeild Recommends for EU Approval by the CHMP for Patients with Stage 2 Type 1 Diabetes

Sanofi Announces Positive Results from the pivotal LIBERTY- AFRS-AIMS Phase 3 Study

Sanofi Announces New Data from the Alphamedix-02 Phase 2 Study Evaluating Alphamedix

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Sanofi's Tzield Accepts for Expanded Review in the US for Stage 3 Type 1 Diabetes Through FDA Commission's National Priority Voucher Pilot Program

Sanofi's High-Dose Influenza Vaccine Demonstrates Superior Protection for Older Adults Against Hospitalization vs Standard-Dose

Sanofi Provides Update on Regulatory Review in the EU for Rezurock to Treat Chronic Graft-Vs-Host Disease

Sanofi's Wayrilz Recommends for Eu Approval by the CHMP to Treat Immune Thrombocytopenia

Sanofi Announces Positive Results from the ALPHAMEDIX-02 Phase 2 Study

Sanofi to Report Q3, 2026 Results on Oct 30, 2026

Sanofi Expands Patient Affordable Program by Offering Access to All Its Insulins for $35 Per Month in the US

Sanofi Announces its SAR446268 Receives US Fast Track Designation for Treatment of Non-Congenital Myotonic Dystrophy Type 1

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Steriles Manufacturing Site in Ridgefield, New Jersey of Sanofi (ENXTPA:SAN).

Sanofi Announces the Us Food and Drug Administration Approves Wayrilz (Rilzabrutinib) in US as First BTK Inhibitor for Immune Thrombocytopenia

Sanofi Confirms Earnings Guidance for the Year 2025

Sanofi's Sarclisa Approves in the EU for the Treatment of Transplant-Efficient Newly Diagnosed Multiple Myeloma

Sanofi Announces BEYFORTUS Reduced Hospital and Doctor Visits for RSV Disease in Babies by 87%

Sanofi (ENXTPA:SAN) entered into an agreement to acquire Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC for $1.6 billion.

Sanofi (ENXTPA:SAN) completed the acquisition of Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC.

Sanofi's Sar446597 Earns Fast Track Designation in the US for Geographic Atrophy Due Toage-Related Macular Debutation

Sanofi Announces Riliprubart Granted Orphan Drug Designation in Japan for Chronic Inflammative Demyelinating Polyneuropathy

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid

Sanofi Accelerates Global Shipping of Beyfortus to Prepare Healthcare Providers Months Ahead of 2025-2026 RSV Season

American Society of Clinical Oncology Announces New Sarclisa Data Support Subcutaneous Administration with On-Body Injector

Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults

Sanofi (ENXTPA:SAN) entered into a definitive merger agreement to acquire Vigil Neuroscience, Inc. (NasdaqGS:VIGL) for approximately $380 million.